JP2012254093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012254093A5 JP2012254093A5 JP2012187148A JP2012187148A JP2012254093A5 JP 2012254093 A5 JP2012254093 A5 JP 2012254093A5 JP 2012187148 A JP2012187148 A JP 2012187148A JP 2012187148 A JP2012187148 A JP 2012187148A JP 2012254093 A5 JP2012254093 A5 JP 2012254093A5
- Authority
- JP
- Japan
- Prior art keywords
- test
- disease
- immune
- sample
- memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 29
- 210000004027 cell Anatomy 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 12
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 11
- 239000012472 biological sample Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 208000026278 immune system disease Diseases 0.000 claims 7
- 230000002757 inflammatory effect Effects 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000013068 control sample Substances 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007824 polyneuropathy Effects 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 241000972773 Aulopiformes Species 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000037319 Hepatitis infectious Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000010362 Protozoan Infections Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000027207 Whipple disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010927 atrophic thyroiditis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000019748 bullous skin disease Diseases 0.000 claims 1
- 239000002458 cell surface marker Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229960000633 dextran sulfate Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000007192 granulomatous hepatitis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 235000019515 salmon Nutrition 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 229940048086 sodium pyrophosphate Drugs 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42247202P | 2002-10-29 | 2002-10-29 | |
| US60/422,472 | 2002-10-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009253394A Division JP2010115195A (ja) | 2002-10-29 | 2009-11-04 | 免疫関連疾患の治療のための新規組成物と方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012254093A JP2012254093A (ja) | 2012-12-27 |
| JP2012254093A5 true JP2012254093A5 (enExample) | 2013-02-14 |
Family
ID=32230357
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004548574A Pending JP2006517785A (ja) | 2002-10-29 | 2003-10-28 | 免疫関連疾患の治療のための新規組成物と方法 |
| JP2009253394A Pending JP2010115195A (ja) | 2002-10-29 | 2009-11-04 | 免疫関連疾患の治療のための新規組成物と方法 |
| JP2012187148A Pending JP2012254093A (ja) | 2002-10-29 | 2012-08-28 | 免疫関連疾患の治療のための新規組成物と方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004548574A Pending JP2006517785A (ja) | 2002-10-29 | 2003-10-28 | 免疫関連疾患の治療のための新規組成物と方法 |
| JP2009253394A Pending JP2010115195A (ja) | 2002-10-29 | 2009-11-04 | 免疫関連疾患の治療のための新規組成物と方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20070185017A1 (enExample) |
| EP (5) | EP2322203A3 (enExample) |
| JP (3) | JP2006517785A (enExample) |
| AU (2) | AU2003298607B9 (enExample) |
| CA (1) | CA2503330A1 (enExample) |
| WO (1) | WO2004039956A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7479555B2 (en) | 1999-07-21 | 2009-01-20 | Ceres, Inc. | Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP4751202B2 (ja) * | 2003-10-30 | 2011-08-17 | 財団法人かずさディー・エヌ・エー研究所 | 新規ＰｌｅｘｉｎポリペプチドとそれをコードするＤＮＡ、及びその用途 |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| WO2005106488A2 (en) * | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2) |
| CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| JP2006042802A (ja) * | 2004-06-28 | 2006-02-16 | Sumitomo Chemical Co Ltd | コモンマーモセット由来のヒポキサンチングアニンホスホリボシルトランスフェラーゼ遺伝子及びその利用 |
| JP4468989B2 (ja) | 2004-08-16 | 2010-05-26 | クアーク・ファーマスーティカルス、インコーポレイテッド | Ｒｔｐ８０１阻害剤の治療への使用 |
| EP2527837A1 (en) * | 2004-10-04 | 2012-11-28 | University of Washington | Methods of inhibiting cell death or inflammation in a mammal |
| DE102004059781A1 (de) * | 2004-12-10 | 2006-06-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung der Serum-/Glucocorticoid regulierten Kinase |
| WO2006069000A2 (en) * | 2004-12-21 | 2006-06-29 | The Brigham And Women's Hospital, Inc. | Klf2 as a mediator of statin activity |
| WO2006091676A2 (en) | 2005-02-22 | 2006-08-31 | Ceres Inc. | Modulating plant alkaloids |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| WO2006133461A1 (en) | 2005-06-08 | 2006-12-14 | Ceres Inc. | Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations |
| DOP2007000015A (es) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | Usos terapéuticos de inhibidores de rtp801 |
| GB2450840B (en) * | 2006-05-11 | 2010-12-29 | Quark Pharmaceuticals Inc | Screening Systems Utilizing RTP801 |
| WO2007141796A2 (en) * | 2006-06-09 | 2007-12-13 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of rtp801l |
| CL2007001614A1 (es) | 2006-06-09 | 2008-08-08 | Novartis Ag | Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t |
| EP2084296B1 (en) * | 2006-09-29 | 2015-08-05 | Agendia N.V. | High-throughput diagnostic testing using arrays |
| WO2008065637A1 (en) * | 2006-12-01 | 2008-06-05 | University College York - National University Of Ireland, Cork | Treatment of disease |
| US7705122B2 (en) * | 2006-12-04 | 2010-04-27 | Intrexon Corporation | mTOR ligands and polynucleotides encoding mTOR ligands |
| EP2114997A2 (de) * | 2006-12-19 | 2009-11-11 | Sanofi-Aventis | Gene mit einem einzigen exon, für neue bioaktive peptide kodierend |
| US7872119B2 (en) | 2007-02-26 | 2011-01-18 | Quark Pharmaceuticals, Inc. | Inhibitors of RTP801 and their use in disease treatment |
| JP2010529843A (ja) * | 2007-06-03 | 2010-09-02 | オンコティーエックス インコーポレイテッド | バイオマーカーおよび薬物標的としての、転写因子複合体の構成要素のがん関連アイソフォーム |
| CA2693677C (en) * | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| DE102007041657A1 (de) * | 2007-09-03 | 2009-03-05 | Protagen Ag | Markersequenzen für Multiple Sklerose und deren Verwendung |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| KR100983475B1 (ko) * | 2008-01-17 | 2010-09-24 | 고려대학교 산학협력단 | 당뇨병성 망막증 진단용 바이오마커 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CA2779436A1 (en) | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
| EP2362877A4 (en) * | 2008-11-06 | 2012-05-09 | Univ Columbia | POLYNUCLEOTIDES CODING FOR HUMAN TRIM-CYP FUSION POLYPEPTIDE, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF |
| US20110311450A1 (en) | 2008-12-08 | 2011-12-22 | Zurit Levine | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| AU2010224160A1 (en) | 2009-03-10 | 2011-09-22 | Biogen Idec Ma Inc. | Anti-BCMA antibodies |
| WO2010141999A1 (en) * | 2009-06-12 | 2010-12-16 | The University Of Queensland | Agents and methods for diagnosing and treating ankylosing spondylitis |
| US8986680B2 (en) * | 2010-04-29 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
| ES2623805T3 (es) | 2010-05-03 | 2017-07-12 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas |
| JP6097690B2 (ja) | 2010-09-02 | 2017-03-15 | ヴァクシネックス， インコーポレイテッド | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
| US10273294B2 (en) | 2010-10-11 | 2019-04-30 | University Of Southern California | Compositions and methods for treating HIF-1α over-expressing cancers |
| US20120121595A1 (en) * | 2010-10-11 | 2012-05-17 | University Of Southern California | FRAGMENT OF SECRETED HEAT SHOCK PROTEIN-90ALPHA (Hsp90ALPHA) AS VACCINES OR EPITOPE FOR MONOCLONAL ANTIBODY DRUGS OR TARGET FOR SMALL MOLECULE DRUGS AGAINST A RANGE OF SOLID HUMAN TUMORS |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| WO2013008095A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| KR102090969B1 (ko) | 2012-03-02 | 2020-03-19 | 백시넥스 인코포레이티드 | Ｂ 세포-매개 염증 질환의 치료 방법 |
| WO2013130188A1 (en) * | 2012-03-02 | 2013-09-06 | Rhode Island Hospital, A Lifespan-Partner | Treating human immunodeficiency virus infections |
| KR102143887B1 (ko) * | 2012-03-16 | 2020-08-12 | 유니버시티 헬스 네트워크 | Toso 활성을 조절하기 위한 방법 및 조성물 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014093417A1 (en) * | 2012-12-12 | 2014-06-19 | University Of Virginia Patent Foundation | Compositions and methods for regulating erythropoiesis |
| US9790271B2 (en) | 2013-01-31 | 2017-10-17 | Vaccinex, Inc. | Methods for increasing immunoglobulin A levels |
| JP6205175B2 (ja) * | 2013-05-16 | 2017-10-04 | 株式会社Ｒｅｓｖｏ | 精神・神経疾患バイオマーカー |
| SI3508502T1 (sl) | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| JP6449338B2 (ja) | 2014-06-06 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| WO2016172524A1 (en) * | 2015-04-23 | 2016-10-27 | Florida Atlantic University | Compositions for inhibiting viral replication and methods of use and production thereof |
| JP6812364B2 (ja) | 2015-06-03 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌診断用抗ｇｉｔｒ抗体 |
| EP4060344A1 (en) | 2015-06-08 | 2022-09-21 | Arquer Diagnostics Limited | Methods and kits |
| JP6854246B2 (ja) | 2015-06-08 | 2021-04-07 | アーケア ダイアグノスティクス リミテッド | 尿サンプルの分析方法 |
| CN108738324B (zh) | 2015-11-19 | 2022-06-21 | 百时美施贵宝公司 | 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途 |
| CA3008686C (en) * | 2015-12-18 | 2023-03-14 | Talengen International Limited | Method for preventing and treating diabetic nephropathy |
| CN109069567A (zh) | 2015-12-18 | 2018-12-21 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
| KR102456731B1 (ko) | 2016-03-03 | 2022-10-24 | 리제너론 파아마슈티컬스, 인크. | Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법 |
| WO2018107703A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种促进胰岛β细胞损伤修复和减少胰岛纤维化的方法 |
| WO2018144775A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| AU2018214451B2 (en) | 2017-02-06 | 2022-02-03 | Meat & Livestock Australia Limited | Immunostimulating compositions and uses therefore |
| KR20200006115A (ko) | 2017-05-16 | 2020-01-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-gitr 효능제 항체에 의한 암의 치료 |
| KR20240155979A (ko) | 2017-05-30 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
| KR102713203B1 (ko) | 2017-05-30 | 2024-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
| BR112020016057A2 (pt) | 2018-02-06 | 2020-12-08 | Meat & Livestock Australia Limited | Polipeptídeo, composições e usos dos mesmos |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| AU2021307452A1 (en) | 2020-07-15 | 2023-02-09 | Biogen Ma Inc. | Implantable cranial medical device |
| AU2021364837A1 (en) | 2020-10-23 | 2023-05-25 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| ATE105585T1 (de) | 1987-12-21 | 1994-05-15 | Univ Toledo | Transformation von keimenden pflanzensamen mit hilfe von agrobacterium. |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE68927344T2 (de) | 1989-04-28 | 1997-02-20 | Rhein Biotech Proz & Prod Gmbh | Hefezellen der Gattung-Schwanniomyces |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| ATE173763T1 (de) * | 1991-08-30 | 1998-12-15 | Hutchinson Fred Cancer Res | Hybride cytokine |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ATE186219T1 (de) | 1993-03-24 | 1999-11-15 | Berlex Biosciences | Kombination von antihormonale und bindende moleküle zur krebsbehandlung |
| US6562333B1 (en) * | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| US6326469B1 (en) * | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP4373495B2 (ja) * | 1995-03-23 | 2009-11-25 | イミュネックス・コーポレーション | Ｉｌ−１７受容体 |
| AU2582897A (en) | 1996-03-15 | 1997-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| US6479254B2 (en) * | 1996-03-22 | 2002-11-12 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II |
| US5861308A (en) * | 1996-08-21 | 1999-01-19 | Ludwig Institute For Cancer Research | Isolated nucleic acids associated with T cell activation and uses thereof |
| JP2002511732A (ja) * | 1996-10-11 | 2002-04-16 | ザ・テキサス・エイ・アンド・エム・ユニヴァーシティ・システム | トランスジェニック動物を発生させるための組成物および方法 |
| US6183951B1 (en) * | 1997-04-11 | 2001-02-06 | Prometheus Laboratories, Inc. | Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy |
| AU764441B2 (en) * | 1998-02-09 | 2003-08-21 | Genset S.A. | cDNAs encoding secreted proteins |
| CA2362427A1 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| WO2000064479A1 (en) * | 1999-04-27 | 2000-11-02 | Antibody Systems, Inc. | Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders |
| EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| JP2002191363A (ja) * | 1999-07-29 | 2002-07-09 | Herikkusu Kenkyusho:Kk | 全長ｃＤＮＡ合成用プライマー、およびその用途 |
| WO2001060860A2 (en) * | 2000-02-17 | 2001-08-23 | Millennium Predictive Medicine, Inc. | Genes differentially expressed in human prostate cancer and their use |
| GB0005345D0 (en) * | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| CA2426508A1 (en) * | 2000-10-23 | 2002-05-16 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
| WO2002068579A2 (en) * | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| AU2002242142A1 (en) * | 2001-02-09 | 2002-08-28 | Johns Hopkins University | A cytokine related structurally to il-17 |
| GB0105402D0 (en) * | 2001-03-05 | 2001-04-18 | Inpharmatica Ltd | Novel proteins |
| WO2003087768A2 (en) * | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
-
2003
- 2003-10-28 EP EP10195515A patent/EP2322203A3/en not_active Ceased
- 2003-10-28 JP JP2004548574A patent/JP2006517785A/ja active Pending
- 2003-10-28 EP EP03796358A patent/EP1576137A4/en not_active Withdrawn
- 2003-10-28 CA CA002503330A patent/CA2503330A1/en not_active Abandoned
- 2003-10-28 EP EP10195513A patent/EP2322202A3/en not_active Ceased
- 2003-10-28 EP EP10195510A patent/EP2322200A3/en not_active Ceased
- 2003-10-28 WO PCT/US2003/034381 patent/WO2004039956A2/en not_active Ceased
- 2003-10-28 AU AU2003298607A patent/AU2003298607B9/en not_active Ceased
- 2003-10-28 EP EP10195512A patent/EP2322201A3/en not_active Ceased
- 2003-10-28 US US10/533,069 patent/US20070185017A1/en not_active Abandoned
-
2009
- 2009-11-04 JP JP2009253394A patent/JP2010115195A/ja active Pending
- 2009-12-24 AU AU2009251206A patent/AU2009251206B2/en not_active Ceased
-
2011
- 2011-02-23 US US13/033,177 patent/US20110245096A1/en not_active Abandoned
-
2012
- 2012-08-28 JP JP2012187148A patent/JP2012254093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012254093A5 (enExample) | ||
| JP2010227106A5 (enExample) | ||
| JP2010187677A5 (enExample) | ||
| JP2010162017A5 (enExample) | ||
| Li | Severe fever with thrombocytopenia syndrome: a newly discovered emerging infectious disease | |
| JP2010220614A5 (enExample) | ||
| JP2011050389A5 (enExample) | ||
| JP2006516094A5 (enExample) | ||
| Schildgen et al. | Human metapneumovirus: lessons learned over the first decade | |
| Margine et al. | Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system | |
| JP2005535290A5 (enExample) | ||
| Dyer et al. | The pneumonia virus of mice (PVM) model of acute respiratory infection | |
| JP2010115195A5 (enExample) | ||
| JP2010511056A5 (enExample) | ||
| JP2007525178A5 (enExample) | ||
| JP2010273685A5 (enExample) | ||
| Mizuta et al. | Molecular evolution of the haemagglutinin–neuraminidase gene in human parainfluenza virus type 3 isolates from children with acute respiratory illness in Yamagata prefecture, Japan | |
| JP2006521082A5 (enExample) | ||
| Zhang et al. | The D253N mutation in the polymerase basic 2 gene in avian influenza (H9N2) virus contributes to the pathogenesis of the virus in mammalian hosts | |
| Kang et al. | Prevalence of severe fever with thrombocytopenia syndrome virus in black goats (Capra hircus coreanae) in the Republic of Korea | |
| Mäntynen et al. | New enveloped dsRNA phage from freshwater habitat | |
| Yadav et al. | Isolation and characterization of Oya virus a member of Simbu serogroup, family Bunyaviridae, isolated from Karnataka, India | |
| CN111212911B (zh) | 与tb7.7特异性结合的dna适体及其用途 | |
| Yuan et al. | Reassortment of avian influenza A/H6N6 viruses from live poultry markets in Guangdong, China | |
| CN105316313A (zh) | 一种高效的细胞融合方法 |